Shijiazhuang No1 Hospital

Shijiazhuang, China

Shijiazhuang No1 Hospital

Shijiazhuang, China
SEARCH FILTERS
Time filter
Source Type

Kang H.J.,Shijiazhuang No1 Hospital | Wang F.,Hebei Medical University | Chen B.C.,Hebei Medical University | Zhang Y.Z.,Hebei Medical University | Ma L.,Hebei Medical University
Knee Surgery, Sports Traumatology, Arthroscopy | Year: 2013

Purpose: The objective of present study was to propose a new classification for acute MPFL injury, which can help choose optimal treatment method for certain injury type. Methods: Eighty-five patients with acute patellar dislocation treated non-surgically were retrospectively reviewed. They were assigned into two groups according to the newly introduced classification scheme, which classified MPFL injury into three types: injury in overlap region, injury in non-overlap region and combined injury of both regions. For study purpose, patients with combined injury were not included. Of 85 patients, 33 were in the overlap-region group (Group 1) and 52 in the non-overlap-region group (Group 2). Clinical patellar instability rate and patellofemoral score were measured and recorded at 2-year follow-up. Results: The patellar instability rate was 15. 2 % in Group 1 and 38. 5 % in Group 2, with statistically significant difference between the two groups (P = 0. 022). The mean visual analogue scale for Group 1 and Group 2 was 15. 6 points and 28. 3 points, respectively (P = 0. 026). The mean Kujala score was 91. 1 points and 82. 6 points (P = 0. 009), with a good or excellent subjective result recorded for 27 of 33 patients (81. 8 %) in Group 1 compared with 30 of 52 patients (57. 7 %) in Group 2 (P = 0. 021). Conclusions: Non-surgical treatment achieves better clinical outcomes with respect to a lower patellar instability rate and better subjective function for the overlap-region injury of MPFL than for the non-overlap-region injury, and can be considered as treatment of choice for overlap-region injury of MPFL. The optimal choice for the non-overlap-region injury still requires further researches. Level of evidence: Therapeutic, Level IV. © 2012 Springer-Verlag.


Zhen Q.,Shijiazhuang No1 Hospital | Liu J.-F.,Hebei Medical University | Liu J.-B.,Shijiazhuang No1 Hospital | Wang R.-F.,Shijiazhuang No1 Hospital | And 5 more authors.
Cancer Biology and Therapy | Year: 2015

Mutations in epidermal growth factor receptor (EGFR) rendering it constitutively active is one of the major causes for metastatic non-small-cell lung cancer (NSCLC), and EGFR-targeted therapies utilizing tyrosine kinase inhibitors (TKIs) are often used clinically as the first-line treatment. But approximately half of NSCLC patients develop resistance to these therapies, where the MET proto-oncogene is amplified by EGFR through the hypoxia-inducible factor (HIF)-1α. Here we report that endothelial PAS domain-containing protein 1 (EPAS1), with 48% sequence identity to HIF-1α, specifically binds to TKI-resistant T790M EGFR, but not to wild-type EGFR, in NSCLC cell lines. Expression of EPAS1 enhances amplification of MET when simultaneously expressed with T790M EGFR but not with wild-type EGFR, and this enhancement is independent of ligand binding domain of EGFR. MET amplification requires EPAS1, since EPAS1 knock-down reduced MET levels. When NSCLC cells expressing T790M EGFR were treated with TKIs, reduced EPAS1 levels significantly enhanced the drug effect, whereas over-expression of EPAS1 increased the drug resistant effect. This EPAS1-dependent TKI-resistance was abolished by knocking-down MET, suggesting that EPAS1 does not cause TKI-resistance itself but functions to bridge EGFR and MET interactions. Our findings suggest that EPAS1 is a key factor in the EGFR-MET crosstalk in conferring TKI-resistance in NSCLC cases, and could be used as a potential therapeutic target in TKI-resistant NSCLC patients. © 2015 Taylor and Francis Group, LLC.


Zhao B.,Shijiazhuang No1 Hospital | Wang K.,Xi'an Jiaotong University | Zhao J.,China Institute of Sport Science
Kuwait Medical Journal | Year: 2016

A 38-year-old male patient suffering from bilateral sternoclavicular (SC) joint dislocation with clavicle fracture was treated with internal fixation using absorbable screw and suture. During the operation, a poly lactic acid (PLA) absorbable screw was inserted into the reset SC joint in a longitudinal direction. Then, polydioxanone (PDS) absorbable suture was penetrated through the bone holes in the sternum ridge and the sternal end of clavicle. The suture was knotted to improve the fixation. A sling to support the forearm was used for three weeks after fixation. Functional exercise was then performed. Six months after the operation, a score of 11 points was achieved and postoperative complications did not appear. The points given were based on Rockwood scores for the evaluation of clinical effects on the patient. The stability of the joint can be achieved in three dimensions and the secondary surgery operation can be avoided. Treating bilateral SC joint dislocation using absorbable screw fixation with an absorbable suture proved to be a satisfactory method. © The Kuwait Medical Journal. All rights reserved.


Wang H.-Y.,Shijiazhuang No1 Hospital | Wang H.-Y.,Tianjin Medical University | Wei R.-H.,Tianjin Medical University | Zhao S.-Z.,Tianjin Medical University
International Journal of Ophthalmology | Year: 2013

The keratoprosthesis (KPro; artificial cornea) is a special refractive device to replace human cornea by using heterogeneous forming materials for the implantation into the damaged eyes in order to obtain a certain vision. The main problems of artificial cornea are the biocompatibility and stability of the tissue particularly in penetrating keratoplasty. The current studies of tissue-engineered scaffold materials through comprising composites of natural and synthetic biopolymers together have developed a new way to artificial cornea. Although a wide agreement that the long-term stability of these devices would be greatly improved by the presence of cornea cells, modification of keratoprosthesis to support cornea cells remains elusive. Most of the studies on corneal substrate materials and surface modification of composites have tried to improve the growth and biocompatibility of cornea cells which can not only reduce the stimulus of heterogeneous materials, but also more importantly continuous and stable cornea cells can prevent the destruction of collagenase. The necrosis of stroma and spontaneous extrusion of the device, allow for maintenance of a precorneal tear layer, and play the role of ensuring a good optical surface and resisting bacterial infection. As a result, improvement in corneal cells has been the main aim of several recent investigations; some effort has focused on biomaterial for its well biological properties such as promoting the growth of cornea cells. The purpose of this review is to summary the growth status of the corneal cells after the implantation of several artificial corneas.


Kang H.,Shijiazhuang No1 Hospital | Cao J.,Shijiazhuang No1 Hospital | Yu D.,Shijiazhuang No1 Hospital
Acta Orthopaedica et Traumatologica Turcica | Year: 2014

Deep vein thrombosis is a rare complication after arthroscopic anterior cruciate ligament reconstruction. We present a patient with primary thrombocytopenia who had deep vein thrombosis after arthroscopic anterior cruciate ligament reconstruction. The patient recovered well at a 2-year follow-up. The purpose of this study was to enhance the awareness on venous thrombosis, a rare complication after arthroscopic anterior cruciate ligament reconstruction. © 2014 Turkish Association of Orthopaedics and Traumatology.


Kang H.J.,Shijiazhuang No1 Hospital | Wang X.J.,Shijiazhuang No1 Hospital | Wu C.J.,Shijiazhuang No1 Hospital | Cao J.H.,Shijiazhuang No1 Hospital | And 2 more authors.
Knee Surgery, Sports Traumatology, Arthroscopy | Year: 2015

Purpose: The purpose of this study was to prospectively compare the outcomes of single-bundle (SB) anterior cruciate ligament (ACL) reconstruction with modified bone-patellar tendon-bone (BPTB) allograft and double-bundle (DB) reconstruction with tibialis anterior allograft. Methods: With 94 patients enroled in the study, 43 subjects who had SB ACL reconstruction with modified BPTB allograft (group S) and 41 subjects of DB ACL reconstruction with tibialis anterior allograft (group D) were followed up for a minimum of 2 years. Clinical outcomes including Lachman and pivot-shift tests, KT-1000 arthrometer measurements, and the International Knee Documentation Committee (IKDC) classification, Lysholm and Tegner activity scores were compared between the two groups at the last follow-up. Results: The mean graft size of the group S, the anteromedial bundle and posterolateral bundle in group D were 9.9 ± 0.2, 7.5 ± 0.4 and 6.6 ± 0.4 mm, with statistically significant difference between the group S graft to either bundle of group D grafts (p < 0.001). At the last follow-up, there was no statistical difference between the two groups for the Lachman test, pivot-shift test and side-to-side difference. Substantial improvements in the subjective knee function scores were achieved in both groups, but without significant difference between the two groups. Conclusions: After a 2-year minimum follow-up, SB ACL reconstruction based on modified BPTB allograft achieved similar clinical outcomes to DB reconstruction with tibialis anterior allograft in knee stability, both anterior-posterior and rotational, as well as knee function. The modified BPTB allograft was recommended as an ideal graft option for the SB ACL reconstruction. Level of evidence: Therapeutic, randomized controlled study, Level II. © 2014, Springer-Verlag Berlin Heidelberg.


PubMed | Shijiazhuang No1 Hospital
Type: Journal Article | Journal: Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA | Year: 2013

The objective of present study was to propose a new classification for acute MPFL injury, which can help choose optimal treatment method for certain injury type.Eighty-five patients with acute patellar dislocation treated non-surgically were retrospectively reviewed. They were assigned into two groups according to the newly introduced classification scheme, which classified MPFL injury into three types: injury in overlap region, injury in non-overlap region and combined injury of both regions. For study purpose, patients with combined injury were not included. Of 85 patients, 33 were in the overlap-region group (Group 1) and 52 in the non-overlap-region group (Group 2). Clinical patellar instability rate and patellofemoral score were measured and recorded at 2-year follow-up.The patellar instability rate was 15.2% in Group 1 and 38.5% in Group 2, with statistically significant difference between the two groups (P=0.022). The mean visual analogue scale for Group 1 and Group 2 was 15.6 points and 28.3 points, respectively (P=0.026). The mean Kujala score was 91.1 points and 82.6 points (P=0.009), with a good or excellent subjective result recorded for 27 of 33 patients (81.8%) in Group 1 compared with 30 of 52 patients (57.7%) in Group 2 (P=0.021).Non-surgical treatment achieves better clinical outcomes with respect to a lower patellar instability rate and better subjective function for the overlap-region injury of MPFL than for the non-overlap-region injury, and can be considered as treatment of choice for overlap-region injury of MPFL. The optimal choice for the non-overlap-region injury still requires further researches.Therapeutic, Level IV.


PubMed | Shijiazhuang No1 Hospital
Type: Journal Article | Journal: Cancer biology & therapy | Year: 2015

Mutations in epidermal growth factor receptor (EGFR) rendering it constitutively active is one of the major causes for metastatic non-small-cell lung cancer (NSCLC), and EGFR-targeted therapies utilizing tyrosine kinase inhibitors (TKIs) are often used clinically as the first-line treatment. But approximately half of NSCLC patients develop resistance to these therapies, where the MET proto-oncogene is amplified by EGFR through the hypoxia-inducible factor (HIF)-1. Here we report that endothelial PAS domain-containing protein 1 (EPAS1), with 48% sequence identity to HIF-1, specifically binds to TKI-resistant T790M EGFR, but not to wild-type EGFR, in NSCLC cell lines. Expression of EPAS1 enhances amplification of MET when simultaneously expressed with T790M EGFR but not with wild-type EGFR, and this enhancement is independent of ligand binding domain of EGFR. MET amplification requires EPAS1, since EPAS1 knock-down reduced MET levels. When NSCLC cells expressing T790M EGFR were treated with TKIs, reduced EPAS1 levels significantly enhanced the drug effect, whereas over-expression of EPAS1 increased the drug resistant effect. This EPAS1-dependent TKI-resistance was abolished by knocking-down MET, suggesting that EPAS1 does not cause TKI-resistance itself but functions to bridge EGFR and MET interactions. Our findings suggest that EPAS1 is a key factor in the EGFR-MET crosstalk in conferring TKI-resistance in NSCLC cases, and could be used as a potential therapeutic target in TKI-resistant NSCLC patients.


PubMed | Shijiazhuang No1 Hospital
Type: Case Reports | Journal: Acta orthopaedica et traumatologica turcica | Year: 2014

Deep vein thrombosis is a rare complication after arthroscopic anterior cruciate ligament reconstruction. We present a patient with primary thrombocytopenia who had deep vein thrombosis after arthroscopic anterior cruciate ligament reconstruction. The patient recovered well at a 2-year follow-up. The purpose of this study was to enhance the awareness on venous thrombosis, a rare complication after arthroscopic anterior cruciate ligament reconstruction.


PubMed | Shijiazhuang No1 Hospital
Type: Comparative Study | Journal: Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA | Year: 2015

The purpose of this study was to prospectively compare the outcomes of single-bundle (SB) anterior cruciate ligament (ACL) reconstruction with modified bone-patellar tendon-bone (BPTB) allograft and double-bundle (DB) reconstruction with tibialis anterior allograft.With 94 patients enroled in the study, 43 subjects who had SB ACL reconstruction with modified BPTB allograft (group S) and 41 subjects of DB ACL reconstruction with tibialis anterior allograft (group D) were followed up for a minimum of 2years. Clinical outcomes including Lachman and pivot-shift tests, KT-1000 arthrometer measurements, and the International Knee Documentation Committee (IKDC) classification, Lysholm and Tegner activity scores were compared between the two groups at the last follow-up.The mean graft size of the group S, the anteromedial bundle and posterolateral bundle in group D were 9.90.2, 7.50.4 and 6.60.4mm, with statistically significant difference between the group S graft to either bundle of group D grafts (p<0.001). At the last follow-up, there was no statistical difference between the two groups for the Lachman test, pivot-shift test and side-to-side difference. Substantial improvements in the subjective knee function scores were achieved in both groups, but without significant difference between the two groups.After a 2-year minimum follow-up, SB ACL reconstruction based on modified BPTB allograft achieved similar clinical outcomes to DB reconstruction with tibialis anterior allograft in knee stability, both anterior-posterior and rotational, as well as knee function. The modified BPTB allograft was recommended as an ideal graft option for the SB ACL reconstruction.Therapeutic, randomized controlled study, Level II.

Loading Shijiazhuang No1 Hospital collaborators
Loading Shijiazhuang No1 Hospital collaborators